1982
Company foundation. First extracts manufactured: Ginkgo Biloba, Vincamine and Scopolamine.
Please be aware that this website is not intended for consumers, as the information provided herein does not refer to finished commercial products that are generally available to the public.
The claims made refer to ingredients only and may not comply with Regulation (EC) No. 1924/2006, the Swiss Federal Act on Foodstuffs and Utility Articles (and related Ordinance), the Swiss Ordinance of the Internal Affairs Department on Information concerning Foodstuffs and Cosmetics, or other relevant regulations in your country. Any claims or statements about the products relating to their health benefits have not been evaluated by the Food and Drug Administration (FDA) and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Any of the ingredients are intended to diagnose, treat, cure, or prevent any disease or health condition.
This website is accessible from various countries around the world. Therefore, it may include statements or information that are not applicable to your country or region.
Company foundation. First extracts manufactured: Ginkgo Biloba, Vincamine and Scopolamine.
The joint venture between Ipsen and Dr. Willmar Schwabe acquired the first shares in the company.
The joint venture acquired 100% of Linnea’s shares and the turnover began an upward trend.
Linnea began to develop an interest in researching medical cannabis and cannabinoids.
Linnea was the first Company worldwide to get a GMP certificate for a cannabidiol (CBD) extract from Swissmedic.
Swissmedic GMP-certificate for CBD extract and CBD isolate.
Swissmedic authorization for Pharmaceutical Preparations, API for Clinical Trials, API for Pharmacies*.
*Pharmaceutical Preparations Ph.Eur. 07/2018:2619 – in compliance with GMP Part II.
Linnea® NioSkin® patented technology with CBD launched.
Federal Office for Public Health (FOPH) authorization for THC products**
** Special authorization/exemption from Federal Law for Swiss Distribution.
Novel food Applications submitted for CBD extract and CBD isolate in the EU and UK.
Pharmaceutical product registered in Argentina containing Linnea CBD extract.
Swissmedic authorization for CBG (cannabigerol) extract.
Novel food applications for CBD validated by FSA in the UK.
Pharmaceutical product containing Linnea’s CBD extract registered in Brazil.
International patent application for Linnea CBD extract 5%.
Pharmaceutical products containing Linnea’s CBD extract registered in Uruguay and Chile.
In the year of its 40th anniversary Linnea trademarked NeaXtracta® and NeaPure® products.
Narcotics license received from Swissmedic to produce and export THC APIs.
CBD Isolate ad CBD 5% extract dossiers validated by EFSA (EU).
NeaXtracta® CBD 5% patent granted in Italy.
Swissmedic GID (Guarantee of Identity) authorization.
Anvisa GMP certification.
CEP application for CBD isolate.
Collaboration with EDQM on the preparation of the CBD and Cannabis flowers monographs.
100% Acquisition of Linnea by Vivalto Partners and Linnea’s Executive Team.
THC extracts (full GMP) launch.
Launch of THC, CBD, CBG combination extracts.
Ongoing collaboration with EDQM on the writing of the Cannabis extracts monograph.
Inauguration of a new dedicated facility for narcotic processing.
GMP authorization granted for all THC products as well as pure CBD and THC:CBD and CBD:CBG combinations.
NeaXtracta® CBD:CBG patent granted in Italy.
Linnea has been sustainably manufacturing high-quality botanical APIs for more than 40 years in our GMP certified facility in Ticino Switzerland. We sell to over 50 different countries all over the globe and serve more than 300 business customers each year.
With a focus on sustainably and the environment we produce natural botanical extracts, cannabinoid isolates and white label solutions for the cannabinoids market. Every ingredient that enters the Linnea production line has been selected to ensure GACP compliance. Since 2016 we have been providing much needed GMP certified ingredients to this emerging global cannabinoid market.
Linnea is committed to ongoing innovation, research and continuing to provide the highest quality cannabinoids to the pharmaceutical, dietary ingredients and cosmetics markets.
Leaders and visionaries in the botanical API industry, Linnea‘s executive team brings experience and valuable insight to everything we do.
Susanne Caspar, CEO of Linnea, has held this position since 2020 and prior to this she has held prestigious leadership positions in various pharmaceutical companies. She has a degree in biology and has completed advanced studies in business management, and healthcare. Under her leadership at Linnea cannabinoid products have come to the forefront of importance and she is excited for Linnea to be contributing positively to the growth of the cannabis industry.
chief executive officer
Proudly working at Linnea for over 17 years, first as Product Manager, Chief Procurement Officer and now as Chief Commercial Officer, he has vast experience in sales holding positions in prestigious global corporations prior to joining Linnea. Giorgio also holds degrees in international political science, management and procurement. He is fluent in seven languages and travels the globe representing Linnea discovering new market opportunities, and supporting business customers.
CHIEF COMMERCIAL OFFICER
Part of Linnea since 2008 and CFO since 2016 he is an experienced finance professional with multiple financial and accounting certifications and long experience working in multinational environments ensuring integrity and accuracy while always managing risk. He applies our mission to the financial aspect of Linnea ensuring that our investment plan for the future is focused on innovation and R&D and we are always thinking strategically with an eye towards improvement and growth enhancement.
chief financial officer
Simone has proudly been working at Linnea for the last 30 years and has been the COO since 2012. He has prestigious accreditations as a chemical and safety engineer and manages all aspects of Linnea‘s manufacturing business from the field to the finished products, always with an eye towards the final consumer. He practices a strong commitment to the highest quality stringent standards in all daily operations. He is also a passionate mentor to the many young employees that start at Linnea helping to boost the careers and lives of others.
chief operations officer
Giorgia has been working at Linnea in the Quality department for over 18 years, and has been Chief Quality Officer and Technical Director since 2019. She has a degree in Industrial Chemistry and has spent most of her career working in quality. She is the responsible Technical Director in charge of the Manufacturing License issued by Swissmedic and she is responsible for the Narcotic License. She is able to handle compliance with worldwide regulatory and quality expectations handling the different certification programs at Linnea. She is also a long time manager and leader at Linnea mentoring many employees at the company.
Chief Quality Officer
Working at Linnea since 2010 and Chief R&D Officer since 2023, he manages the R&D department and overseas research and product innovation at Linnea. He holds a masters degree in organic chemistry, and has held important positions in R&D throughout his career, working on optimizing API production for the marketplace. He is a passionate diverse thinker focused on rigorous research, new discoveries and sustainable harmonious applications of natural ingredients for Linnea’s products.
CHIEF R&D OFFICER
Joined the pharma industry in 2012 as in-house counsel for a multinational company, in Linnea since 2020 as Legal Counsel & Compliance Officer. She is a qualified attorney in Italy and USA, has gained solid experience in contract drafting and corporate matters in international law firms based in Switzerland. Always striving to support the business in very diverse commercial contract scenarios and to ensure that legal compliance and ethics principles are adhered to across the organization.
Legal Counsel & Compliance Officer
Linnea is a member of leading medical cannabis associations across Europe, underscoring the company’s commitment to a responsible, regulated, and science-based industry approach.
We support the development of high-quality standards, robust regulatory frameworks, and best practices that strengthen the European medical cannabis ecosystem. These memberships allow us to remain closely aligned with regulatory developments, clinical insights, and market expectations across key European markets.
Our engagement reflects our belief that medical cannabis must be built on quality, compliance, and patient trust —ensuring its role as a credible and sustainable therapeutic option.